Thermo Fisher (TMO) Surges 9.7% on Q2 Earnings Beat
Thermo Fisher Scientific (TMO) shares surged 9.7% after reporting Q2 2025 earnings that topped Wall Street expectations. Revenue reached $11.99 billion (up 10.5% YoY) and adjusted EPS came in at $6.03, exceeding the $5.71 consensus.
Key Numbers
Thermo Fisher Scientific (NYSE:TMO) reported strong second-quarter 2025 earnings that beat analyst estimates, sending its stock up 9.7% in afternoon trading.
Key Financial Results
| Metric | Value | Estimate | YoY Change |
|---|---|---|---|
| Revenue | $11.99B | $11.72B | +10.5% |
| Adjusted EPS | $6.03 | $5.71 | — |
| Organic Growth | — | — | +5% |
Highlights from the Release
The company attributed the strong performance to growth in diagnostics and analytics segments, as well as sustained demand for laboratory equipment. Improved supply chains also contributed to revenue.
Guidance
The company did not provide specific guidance for the next quarter, but management expressed confidence in maintaining positive momentum.
Stock Impact
The stock jumped 9.7% in afternoon trading, reflecting investor optimism over the earnings beat and robust revenue growth.
What This Means for Investors
The results demonstrate Thermo Fisher's resilience amid changing market conditions. However, future performance will depend on sustained demand for life sciences products and sector developments.
Frequently Asked Questions
Found this useful? Share it